Janssen Research & Development, LLC
Janssen Research & Development, LLC is the pharmaceutical research arm of Johnson & Johnson, one of the world's largest healthcare companies. Operating through the Janssen Pharmaceutical Companies — including Janssen-Cilag, Janssen Biologics, and other regional entities — J&J's pharmaceutical division runs one of the most diversified clinical trial programs in the industry, spanning oncology, immunology, neuroscience, cardiovascular and metabolism, and pulmonary hypertension.
Janssen's oncology portfolio centers on hematological malignancies, particularly multiple myeloma (daratumumab/Darzalex combinations, teclistamab bispecific, ciltacabtagene autoleucel CAR-T), prostate cancer (apalutamide/Erleada, niraparib combinations), and solid tumors. In immunology, Janssen's IL-12/23 inhibitor guselkumab (Tremfya) and IL-23 inhibitors are central to a broad pipeline in psoriatic disease, IBD, and systemic lupus. Esketamine (Spravato), an intranasal ketamine derivative for treatment-resistant depression, reflects the neuroscience program's push into rapid-onset antidepressants and suicidality intervention.
Janssen operates a global clinical development network with research sites across North America, Europe, Asia-Pacific, Latin America, and the Middle East. The company has made significant investments in decentralized and hybrid trial designs, electronic patient-reported outcomes, and real-world evidence integration. Through Johnson & Johnson's Global Public Health unit, Janssen also conducts trials on vaccines and treatments for HIV, tuberculosis, and Ebola — often in partnership with NIH, BARDA, and the Bill & Melinda Gates Foundation.